Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Intrahepatic mRNA Expression of FAS, FASL, and FOXP3 Genes Is Associated with the Pathophysiology of Chronic HCV Infection.

Amoras Eda S, Gomes ST, Freitas FB, Santana BB, Ishak G, Ferreira de Araújo MT, Demachki S, Conde SR, Ishak Mde O, Ishak R, Vallinoto AC.

PLoS One. 2016 May 31;11(5):e0156604. doi: 10.1371/journal.pone.0156604. eCollection 2016.

2.

Hepatitis C virus infection: establishment of chronicity and liver disease progression.

Kwon YC, Ray RB, Ray R.

EXCLI J. 2014 Aug 27;13:977-96. eCollection 2014. Review.

3.

Hepatitis C virus and host cell nuclear transport machinery: a clandestine affair.

Bonamassa B, Ciccarese F, Antonio VD, Contarini A, Palù G, Alvisi G.

Front Microbiol. 2015 Jun 19;6:619. doi: 10.3389/fmicb.2015.00619. eCollection 2015. Review.

4.

Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?

Janardhan SV, Reau NS.

Hepat Med. 2015 Apr 16;7:11-20. doi: 10.2147/HMER.S79584. eCollection 2015. Review.

5.

Disruption of Bcl-2 and Bcl-xL by viral proteins as a possible cause of cancer.

Alibek K, Irving S, Sautbayeva Z, Kakpenova A, Bekmurzayeva A, Baiken Y, Imangali N, Shaimerdenova M, Mektepbayeva D, Balabiyev A, Chinybayeva A.

Infect Agent Cancer. 2014 Dec 23;9:44. doi: 10.1186/1750-9378-9-44. eCollection 2014. Review.

6.

Hepatitis C virus nonstructural protein 5A inhibits thapsigargin-induced apoptosis.

Jiang X, Kanda T, Wu S, Nakamoto S, Wakita T, Shirasawa H, Yokosuka O.

PLoS One. 2014 Nov 19;9(11):e113499. doi: 10.1371/journal.pone.0113499. eCollection 2014.

7.

Viral carcinogenesis: factors inducing DNA damage and virus integration.

Chen Y, Williams V, Filippova M, Filippov V, Duerksen-Hughes P.

Cancers (Basel). 2014 Oct 22;6(4):2155-86. doi: 10.3390/cancers6042155. Review.

8.

Hepatitis C virus and hepatocellular carcinoma.

Kanda T, Yokosuka O, Omata M.

Biology (Basel). 2013 Jan 30;2(1):304-16. doi: 10.3390/biology2010304.

9.

The modulation of apoptosis by oncogenic viruses.

Fuentes-González AM, Contreras-Paredes A, Manzo-Merino J, Lizano M.

Virol J. 2013 Jun 6;10:182. doi: 10.1186/1743-422X-10-182. Review.

10.

Hepatitis C virus-induced mitochondrial dysfunctions.

Brault C, Levy PL, Bartosch B.

Viruses. 2013 Mar 21;5(3):954-80. doi: 10.3390/v5030954. Review.

11.

TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION.

Cordek DG, Bechtel JT, Maynard AT, Kazmierski WM, Cameron CE.

Drugs Future. 2011 Sep;36(9):691-711.

12.

Hepatitis C virus and hepatocarcinogenesis.

Jeong SW, Jang JY, Chung RT.

Clin Mol Hepatol. 2012 Dec;18(4):347-56. doi: 10.3350/cmh.2012.18.4.347. Epub 2012 Dec 21. Review.

13.

Hepatitis C virus activates Bcl-2 and MMP-2 expression through multiple cellular signaling pathways.

Li Y, Zhang Q, Liu Y, Luo Z, Kang L, Qu J, Liu W, Xia X, Liu Y, Wu K, Wu J.

J Virol. 2012 Dec;86(23):12531-43. doi: 10.1128/JVI.01136-12. Epub 2012 Sep 5.

14.

A Role for RNA Viruses in the Pathogenesis of Burkitt's Lymphoma: The Need for Reappraisal.

van den Bosch C.

Adv Hematol. 2012;2012:494758. doi: 10.1155/2012/494758. Epub 2011 Nov 29.

15.

Oncogenic potential of hepatitis C virus proteins.

Banerjee A, Ray RB, Ray R.

Viruses. 2010 Sep;2(9):2108-33. doi: 10.3390/v2092108. Epub 2010 Sep 27.

16.

Nonvirion protein of novirhabdovirus suppresses apoptosis at the early stage of virus infection.

Ammayappan A, Vakharia VN.

J Virol. 2011 Aug;85(16):8393-402. doi: 10.1128/JVI.00597-11. Epub 2011 Jun 8.

17.

Genetic history of hepatitis C virus in Venezuela: high diversity and long time of evolution of HCV genotype 2.

Sulbarán MZ, Di Lello FA, Sulbarán Y, Cosson C, Loureiro CL, Rangel HR, Cantaloube JF, Campos RH, Moratorio G, Cristina J, Pujol FH.

PLoS One. 2010 Dec 13;5(12):e14315. doi: 10.1371/journal.pone.0014315.

18.

Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges.

Bouchard MJ, Navas-Martin S.

Cancer Lett. 2011 Jun 28;305(2):123-43. doi: 10.1016/j.canlet.2010.11.014. Epub 2010 Dec 18. Review.

19.

Bax inhibitor-1 down-regulation in the progression of chronic liver diseases.

Kotsafti A, Farinati F, Cardin R, Burra P, Bortolami M.

BMC Gastroenterol. 2010 Apr 1;10:35. doi: 10.1186/1471-230X-10-35.

20.

Viral hepatocarcinogenesis.

Tsai WL, Chung RT.

Oncogene. 2010 Apr 22;29(16):2309-24. doi: 10.1038/onc.2010.36. Epub 2010 Mar 15. Review.

Supplemental Content

Support Center